
Commentary|Videos|September 16, 2024
Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC
Author(s)Sanjay Popat, BSc, MBBS, FRCP, PhD
Fact checked by: Ashling Wahner , Kristi Rosa
Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.
Advertisement
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research, discusses findings from the second interim overall survival (OS) analysis of the phase 3 MARIPOSA-2 study (NCT04988295) investigating amivantamab-vmjw (Rybrevant) plus chemotherapy in patients with EGFR-mutated, advanced non–small cell lung cancer who have progressed on osimertinib (Tagrisso).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































